Medical treatment of symptomatic uterine leiomyomata in premenopausal woman;Traitements médicaux chez la femme ayant des myomes symptomatiques en période d'activité génitale

Presse Medicale

Volumn 42, Issue 7-8, 2013, Pages 1122-1126

  Koskas, Martin ^a   Derrien, Jean ^b  

^a BICHAT HOSPITAL   (France)

^b Collège de gynécologie RhÔne Alpes ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ESTROGEN; FADROZOLE; GESTAGEN; GONADORELIN AGONIST; HEMOGLOBIN; LETROZOLE; LEVONORGESTREL; LYNESTRENOL; MIFEPRISTONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREGNANE DERIVATIVE; TIBOLONE; TRANEXAMIC ACID; ULIPRISTAL;

BLEEDING DISORDER; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DYSMENORRHEA; ENDOMETRIUM HYPERPLASIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; MENSTRUATION; METRORRHAGIA; PELVIS PAIN SYNDROME; PREMENOPAUSE; SHORT SURVEY; TREATMENT RESPONSE; UTERUS MYOMA;

ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE MANAGEMENT; FEMALE; HUMANS; LEIOMYOMA; PREMENOPAUSE; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 84879411669     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.02.318     Document Type: Short Survey

References (26)

1. Lumsden M.A., Wallace E.M. Clinical presentation of uterine fibroids. Baillieres Clin Obstet Gynaecol 1998, 12:177-195.
2. Marino J.L., Eskenazi B., Warner M., Samuels S., Vercellini P., Gavoni N., et al. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Reprod 2004, 19:2350-2355.
3. DeWaay D.J., Syrop C.H., Nygaard I.E., Davis W.A., Van Voorhis B.J. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 2002, 100:3-7.
4. Pron G., Cohen M., Soucie J., Garvin G., Vanderburgh L., Bell S. The Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life. Fertil Steril 2003, 79:112-119.
5. Chen C.R., Buck G.M., Courey N.G., Perez K.M., Wactawski-Wende J. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 2001, 153:20-26.
6. Huchon C., Fritel X. Epidemiology of menometrorrhagia. J Gynecol Obstet Biol Reprod 2008, 37(Suppl. 8):S307-S316.
7. Robboy S.J., Bentley R.C., Butnor K., Anderson M.C. Pathology and pathophysiology of uterine smooth-muscle tumors. Environ Health Perspect 2000, 108(Suppl. 5):779-784.
8. Haney A.F. Clinical decision making regarding leiomyomata: what we need in the next millenium. Environ Health Perspect 2000, 108(Suppl. 5):835-839.
9. Hodges L.C., Houston K.D., Hunter D.S., Fuchs-Young R., Zhang Z., Wineker R.C., et al. Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells. Mol Cell Endocrinol 2002, 196:11-20.
10. Lethaby A., Vollenhoven B., Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG 2002, 109:1097-1108.
11. Broekmans F.J. GnRH agonists and uterine leiomyomas. Hum Reprod 1996, 11(Suppl. 3):3-25.
12. Felberbaum R.E., Kupker W., Diedrich K. Will GnRH antagonists assist in the treatment of benign gynaecological diseases?. Reprod Biomed Online 2002, 5(Suppl. 1):68-72.
13. Ke L.Q., Yang K., Li J., Li C.M. Danazol for uterine fibroids. Cochrane Database Syst Rev 2009, 3:CD007692.
14. Chabbert-Buffet N., Meduri G., Bouchard P., Spitz I.M. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005, 11:293-307.
15. Williams A.R., Critchley H.O., Osei J., Ingamells S., Cameron I.T., Han C., et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007, 22:1696-1704.
16. Chwalisz K., Larsen L., Mattia-Goldberg C., Edmonds A., Elger W., Winkel C.A. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007, 87:1399-1412.
17. Wilkens J., Chwalisz K., Han C., Walker J., Cameron I.T., Ingamells S., et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008, 93:4664-4671.
18. Nieman L.K., Blocker W., Nansel T., Mahoney S., Reynolds J., Blithe D., et al. Efficacy and tolerability of CDB-2914treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril 2011, 95(767-772):e1-e2.
19. Levens E.D., Potlog-Nahari C., Armstrong A.Y., Wesley R., Premkumar A., Blithe D.L., et al. CDB-2914for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008, 111:1129-1136.
20. Donnez J., Tomaszewski J., Vazquez F., Bouchard P., Lemieszczuk B., Baro F., et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012, 366:421-432.
21. Sener A.B., Seckin N.C., Ozmen S., Gokmen O., Dogu N., Ekici E. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril 1996, 65:354-357.
22. Ylostalo P., Granberg S., Backstrom A.C., Hirsjarvi-Lahti T. Uterine findings by transvaginal sonography during percutaneous estrogen treatment in postmenopausal women. Maturitas 1996, 23:313-317.
23. Polatti F., Viazzo F., Colleoni R., Nappi R.E. Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. Maturitas 2000, 37:27-32.
24. Palomba S., Sena T., Noia R., Di Carlo C., Zullo F., Mastrantonio P. Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. Obstet Gynecol 2001, 98:1053-1058.
25. Palomba S., Sena T., Morelli M., Noia R., Zullo F., Mastrantonio P. Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2002, 102:199-201.
26. Fraser I.S., McCarron G., Markham R., Resta T., Watts A. Measured menstrual blood loss in women with menorrhagia associated with pelvic disease or coagulation disorder. Obstetrics and gynecology 1986, 68:630-633.